Camizestrant, AZD 9833 AZ 14066724 FDA 2026, APPROVALS 2026, Etcamah To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy CAS: 2222844-89-3Chemical Formula: C24H28F4N6Exact Mass: 476.2312Molecular Weight: 476.5236Elemental Analysis: C, 60.49; H, 5.92; F, 15.95; N, 17.64 … Continue reading Camizestrant, AZD 9833